Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments
In January 2024, the U.S. Food and Drug Administration (FDA) required labeling information for all currently available CAR T-cell therapies to include a boxed warning advising prescribers and patients of the potential risks ...
13 hours ago
0
0